Background: Demineralized dentin matrix (DDM) has potential application as a carrier for
| INTRODUCTION
Recombinant human bone morphogenetic protein-2 (rhBMP-2) when delivered via a carrier leads to clinically relevant bone formation. 1 Collagen is the best documented carrier for exogenous rhBMP-2. In 2007, the US Food and Drug Administration (FDA) approved the use of rhBMP-2 at a concentration of 1.5 mg/mL in an absorbable collagen sponge (ACS) for sinus floor augmentation and socket preservation. 1 However, there have been concerns about the safety of rhBMP-2 with regard to dose-dependent complications, such as edema and heterotopic bone formation, as well as off-label use. 2 However, no complications were noted when surgeons reduced the dose to one quarter or one half of the FDA-approved dose. 2, 3 rhBMP-2-induced soft tissue inflammation has been observed in response to exogenous application of BMP in a rodent model and was reduced when rhBMPs were delivered using a slowrelease carrier. 2 Collagen has a limited capacity for controlled release, and most of the absorbed agent is released on the day following implantation. 4 Implantation of rhBMP-2 by an ACS increases the potential for leakage of rhBMP-2 and formation of ectopic bone. 5 In comparison with carriers composed solely of hydroxyapatite, composites consisting of hydroxyapatite, tricalcium phosphate, and collagen result in improved local delivery of BMP and formation of orthotopic bone. 6, 7 Urist was the first to report that dentin is an osteoinductive material that causes connective tissue to convert to bone by endochondral osteogenesis. 8 In 1991, Bessho et al. successfully isolated BMP from the human dentin matrix. 9 Although human dentin-derived BMP is different from human bone-derived BMP, the two types of BMP have the same action in the body. 9 The quantity of endogenous BMP in extracted teeth was very small or nil compared with that of the cortical bone (<1 μg/kg).
10,11
Recently, Nina Bono reported that demineralized deciduous tooth contained 1.2 AE 0.3 ng of BMP-2 per g of tooth particles. 12 The physical properties of dentin, including density, roughness, and homogeneity, and its physiochemical characteristics, including dissolution of calcium/phosphate ions, are similar to those of human cortical bone. 13 Structurally, the dentin matrix consists of dentinal tubules measuring 1-3 μm in diameter with a porosity of 3.70%-5.88%
that can be increased by demineralization. 13 Demineralized dentin matrix (DDM) is defined as an acid- have demonstrated that DDM has the highest released-to-loaded rhBMP-2 ratio, the slowest rate of release, and the highest induction of osteonectin expression, resulting in augmented formation of mature bone. 13 On the basis of the osteoinductive activity of DDM and its potential as a carrier for rhBMP-2, as well as the reported synergistic effects of rhBMP-2 and transforming growth factor beta in a variety of model systems, 13, [16] [17] [18] we hypothesized that the effect of DDM/rhBMP-2 on socket preservation may be superior to that of DDM alone. Moreover, we expected synergistic effects between exogenous rhBMP-2 and the endogenous growth factors in osteoinductive DDM that could allow the ideal concentration of exogenous rhBMP-2 to be lowered. 3, 19 The aim of this case series study was to compare the efficacy of autogenous DDM/rhBMP-2 for socket preservation with that of autogenous DDM alone. The primary variables were the changes in height and width of the extraction socket 3-6 months after the graft procedure. The secondary variables were the amount of bone formation and residual dentin.
| MATERIALS AND METHODS

| Study design
The study was conducted in accordance with the Declaration of Helsinki and the protocol was approved by the Ethics Committee at Seoul National University of Bundang Hospital (B-1441/274-106).
Patients were considered for enrollment in the study if they had teeth that needed to be extracted and could be used to make autoge- 
| Preparation of DDM and DDM/rhBMP-2
DDM powder was produced from the extracted human teeth according to the protocol used at the Korea Tooth Bank (Seoul, Korea). First, the teeth were soaked in 70% ethyl alcohol. After dividing each tooth into a crown and root, the root portion was collected and crushed to a powder containing particles measuring 300-800 μm in diameter. The crushed particles were soaked in distilled water and a hydrogen dioxide solution, and the remaining foreign substances were removed using an ultrasonic cleaner. The cleaned particles were dehydrated with ethyl alcohol and subjected to defatting using ethyl ether solutions. The particles were then demineralized for 30 min in 0.6 N HCl.
The demineralized particles were lyophilized and sterilized with ethylene oxide gas and stored at room temperature for clinical use. 
| Surgical procedure
In the experimental group, a period of at least 4 weeks was allowed for resolution of the inflammation remaining at the extraction site.
Surgery was performed under local anesthesia using 2% lidocaine HCl with epinephrine (1:100,000; Xylestesin-A, 3M ESPE, Seefeld, Germany). After incision and flap elevation, the preservation procedures were performed using DDM or DDM/rhBMP-2. Primary closure of the surgical sites was performed without covering membranes.
The patients were instructed to rinse the mouth twice per day with a 0.1% chlorhexidine solution and to take oral antibiotics (amoxicillin and clavulanate 625 mg, Ilsung Pharmaceutical Co., Seoul, Korea) three times daily for 5 days. Uneventful healing was observed at all sites at the follow-up visit on day 7. There were no reports or signs of inflammation, infection, or graft rejection. 
| Measurement of dimensional changes
A CBCT scan of the area of interest was taken immediately after socket preservation and before trephine core harvesting 3-6 months after the graft procedure to measure the dimensional changes in the alveolar extraction socket. The height measurements were performed using linear measurement tools in a cross-sectional slice from the crest to the base of the extraction socket. The width was measured from the remaining buccal cortical bone summit to that of the lingual cortical bone (Figures 1 and 2 ).
| Histomorphometric analysis
Tissues from the trephine cores were processed for histological evaluation. Two 5-μm-thick sections that contained whole defects were selected and stained with hematoxylin and eosin and immunostained. 
| Statistical analysis
Summaries of the CBCT analysis and histomorphometric measurements were obtained using descriptive analysis and are shown as the mean and SD. The two-samples t-test was used to compare variables that were normally distributed and the Mann-Whitney U test was used to compare variables that were not normally distributed. The statistical analyses were performed using IBM SPSS Statistics version 19.0 software (IBM Corp., Armonk, NY). A P-value <.05 was considered statistically significant.
| RESULTS
| Dimensional changes
The height reductions after application of DDM/rhBMP-2 and DDM were 2.51% and 6.14%, respectively; the respective width reductions were 5.95% and 7.61% ( Table 2 ). The reductions in height and width were smaller in the DDM/rhBMP-2 group than in the DDM group.
The differences between the groups were not statistically significant for height (P = .428, Mann-Whitney U test) or width (P = .713, MannWhitney U test; Table 2 and Figure 2 ).
| Histomorphometric analysis
On histological evaluation, osteoinductive and osteoconductive bone formation was observed around the DDM particles in the DDM group. The DDM particles were surrounded by dense fibrous connective tissue. In contrast, active bone formation with embedding of osteocytes and a lining of osteoblasts was observed in the DDM/rhBMP-2 group and the particles were surrounded by highly vascularized loose areolar tissues (Figure 3 ).
In the DDM/rhBMP-2 group, there was collagenolytic resorption of the dentin matrix with infiltration of adipocytes, and the reminiscent of DDM in the newly formed bone was being resorbed by multinucleated giant cells (Figure 4 ).
The mean proportion of newly formed bone was 34.39% AE 19.05%
in the DDM/rhBMP-2 group and 29.75% AE 12.62% in the DDM group; the respective mean proportions of residual dentin were 8.35% AE 9.34% and 16.15% AE 17.17%. In terms of soft tissue components, the average proportions were 53.27% AE 20.30% in the DDM/rhBMP-2 group and 35.87% AE 17.10% in the DDM group ( Figure 5 ).
There was no statistically significant difference in the amount of new bone formation, residual dentin, or soft tissue between the groups (P = .606, two-samples t-test, for new bone formation; P = .713, Mann-Whitney U test, for residual dentin; and P = .101, two-samples t-test, for soft tissue components). Although the differences were not statistically significant, the dimensional changes, amount of bone formation, and replacement of DDM with bone in the DDM/rhBMP-2 group were superior to the respective values in the DDM group.
| DISCUSSION
The aim of this case series study was to evaluate the efficacy of autogenous DDM/rhBMP-2 in human socket preservation. Our expectation was that exogenous rhBMP-2 loaded into DDM and the endogenous growth factors in DDM would have synergistic effects that could allow the concentration of rhBMP-2 to be reduced from the currently approved concentration of 1.5 mg/mL to 0.2 mg/mL when used with an ACS. FIGURE 2 Changes in height and width according to CBCT images. The mean height reduction was 2.51% in the DDM/rhBMP-2 group and 6.14% in the DDM group; the respective mean width reductions were 5.95% and 7.61%. The reduction of height was less after DDM/rhBMP-2 treatment than after DDM treatment. There was no statistically significant between-group difference in height (P = .428, Mann-Whitney U test) or width (P = .713, Mann-Whitney U test). CBCT, cone beam computed tomography; DDM, demineralized dentin matrix; DDM/rhBMP-2, DDM loaded with recombinant human bone morphogenetic protein-2 Dimensional changes in the residual alveolar ridge are inevitable following tooth extraction, and preexisting periodontal disease hastens the process of bone resorption. 21 To confirm the synergistic effect, we applied DDM/rhBMP-2 to the extraction socket in cases of chronic advanced periodontitis.
The reductions in height and width were smaller after application of DDM/rhBMP-2 than after application of DDM alone. The average reductions in height (0.27 mm) and width (0.47 mm) in the DDM/rhBMP-2 group in the course of 3-6 months were far smaller than the conventional reported reductions (1.53 mm for height and 3.87 mm for width).
22
The alveolar ridge loses more than 50% of its height and width within the first 6 months after tooth extraction. The resorption rate at the alveolar ridge is highest during the first 6 months after extraction, and proceeds at an average rate of 0.5%-1.0% per year thereafter. Although it is difficult to predict the amount of bone resorption after extraction, the findings of the present study indicate that DDM/rhBMP-2 has a promising effect in terms of preservation of the extraction socket for implant placement.
Bone formation was slightly greater after treatment with DDM/rhBMP-2 than after treatment with DDM, but the difference was not statistically significant. However, the amount of bone formation 3-6 months after the graft is noteworthy (34.39% in the DDM/rhBMP-2 group and 29.75% in the DDM group) considering that the concentration of rhBMP-2 used in this study was 0.2 mg/mL, which is approximately seven times lower than the presently approved concentration. The amount of bone formation 4 weeks after grafting in a rabbit calvarial defect model was reported to be greater in a group that was treated with DDM/rhBMP-2 0.2 mg/mL than in a group that was treated with DDM alone (47.99% vs 24.94%).
17
Along with the superior effects of BMP-2/ACS in preclinical models, clinical studies have demonstrated successful results thereby preserving the ridge height and significantly increasing the width at 75%, 50%, and 25% of the extraction socket length. In addition, there were no differences in the histology of the core bone biopsies between rhBMP-2-induced bone and native bone. 27 There was less residual dentin after treatment with DDM/rhBMP-2 than after treatment with DDM alone; however, the difference was not statistically significant. Experimental studies of human dentin grafts in a rabbit model showed that the remodeling resorption process involves continuous resorption of dentin with bone replacement in the dentin resorption cavities after 6 months. 28 In a clinical study comparing DDM with anorganic bovine bone, the residual graft material was 8.95% in the DDM group and 17.08% in the anorganic bovine bone group. 29 In our preliminary clinical report, histological specimens of DDM/rhBMP-2 obtained at the time of second surgery had multiple irregularly shaped surfaces infiltrated by activated cells, as well as isolated spaces that became filled with infiltrating cells. 19 These spaces were consistent with collagenolytic resorption and fibroblast infiltration and were reminiscent of DDM undergoing resorption by multinucleated giant cells. These observations seem consistent with the reports of Ike and Urist 14 and Murata, 15 which showed that as the quantity of induced bone increased after treatment with DDM/rhBMP-2, the resorption and replacement of the dentin matrix (carrier) also increased. Even though the authors of those reports did not explain the exact mechanism of dentin resorption, it may be that the resorption of dentin occurs in response to activation of osteoclasts by exogenous rhBMP-2 and that rhBMP-2 stimulates osteoclastic bone resorption in a dose-dependent manner and acts as a mediator of osteoblast-osteoclast interaction. 30 It seems that the exogenous rhBMP-2 released from the DDM carrier at an early stage may promote both osteoinduction and collagenolysis, resulting in enhanced release of endogenous growth factors from the resorbed dentin matrix that, in turn, initiates coupling with osteoblastic bone formation at a later stage.
The concentration of rhBMP-2 that is most effective in promoting bone formation is still unclear, but would be influenced by various factors, including the delivery system, release kinetics, and recipient site. 31 In a canine sinus model, osteogenic activity of BMP-2 was observed even at the lowest dose (0.1 mg/mL, corresponding to 0.02 mg of BMP-2), and this value was 15 times lower than the concentration presently approved for human use (1.5 mg/mL with the ACS); nevertheless, this dose induced twice the amount of bone regeneration than that achieved by the control.
32
In humans, the approved concentration of rhBMP-2 contains relatively high (supraphysiologic) amounts of proteins, so the incidence of side effects is increased. An initial burst release of rhBMP-2 was not inevitably required for osteoinduction, 13 ,20 so we could use a single dose of 0.2 mg/mL, which is lower than the dose of 0.43 mg/mL reported to be effective for inducing bone formation in a sinus augmentation study. 33 The reduced concentration of rhBMP-2 does not trigger a clinically relevant inflammatory response. However, the replacement of the dentin matrix with newly formed bone supports our prediction that endogenous growth factors could be released via resorption of the dentin matrix and show synergism with exogenous rhBMP-2.
16
The resorption of the dentin matrix that occurred in our DDM/rhBMP-2 group within 3-6 months is different from the higher rate of resorption of DDM with the increasing level of demineralization that occurs during the long-term remodeling of dentin grafts. 30 However, the mechanism via which rhBMP-2 increases the rate of selective dentin resorption without impeding bone formation is not fully understood. Moreover, we have yet to determine whether the increased bone formation is the result of synergistic effects of exogenous and endogenous growth factors or solely attributable to the release of endogenous growth factors via resorption of the dentin matrix. Furthermore, the rhBMP-2 concentration most suitable for use with DDM remains to be identified.
Nevertheless, in the present study, we successfully preserved the alveolar socket for implant dentistry without any complications. This study should be regarded as a case series with a small number of samples and heterogeneous indications. Further studies of the appropriate dosage of rhBMP-2 and mechanism of enhanced dentin resorption are necessary.
| CONCLUSION
We still do not know the most suitable concentration of rhBMP-2 and the exact mechanism of enhanced resorption of the dentin matrix. FIGURE 5 Histomorphometric measurement of new bone formation, residual dentin, and soft tissue. The percentages of newly formed bone were 34.39% AE 19.05% for DDM/rhBMP-2 and 29.75% AE 12.62% for DDM; the respective mean percentages of residual dentin were 8.35% AE 9.34% for DDM/rhBMP-2 and 16.15% AE 17.17% for DDM. In terms of soft tissue components, the average percentages were 53.27% AE 20.30% for DDM/rhBMP-2 and 35.87% AE 17.10% for DDM. As the amount of newly formed bone increased, there was a decrease in the amount of residual dentin in the DDM/rhBMP-2 group. There was no statistically significant between-group difference in the amount of new bone formation (P = .606, two-samples t-test), residual dentin (P = .713, MannWhitney U test), or the soft tissue component (P = .101, two-samples t-test). DDM, demineralized dentin matrix; DDM/rhBMP-2, DDM loaded with recombinant human bone morphogenetic protein-2
However, the observations made in this study may explain why DDM could be a potential carrier for rhBMP-2 as well as the synergistic effects of exogenous rhBMP-2 and endogenous growth factor in DDM.
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